VasQ and A
The FDA has approved VasQ, a new device to reduce fistula failure, for a 2-year clinical trial with 129 patients. The device keeps fistulas from growing too large by providing an external support.
Read the full article » | Posted 08-17-2017
Related Articles
- Proof of Concept for Silicon Nanopore Membrane Implantable HD Posted 10-05-2026
- AWAK PD To Go Posted 10-05-2026
- The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
- Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026